Product Pipeline
Urological Diseases
Product
Target/Type
Region
Pre-Clinical
IND
Phase I
Phase II
Pivotal/Phase III
NDA
1First-In-Class (Global Pioneer) Vesique® (APL-1202)
MetAP2
Global
China
NMIBC (Second-line treatment in combination with chemotherapy)
China
NMIBC (First-line monotherapy)
USA
NMIBC (Second-line treatment in combination with BCG)
USA, China
Neoadjuvant therapy for MIBC (In combination with tislelizumab). Partner: 
APL-1501
MetAP
Global
Australia
Urological tumors/Resistant urological tract infections
Hexvix® (APL-1706)
Photosensitizer
China
NMIBC diagnosis and operation.
Partner: 
Reproductive Diseases
Product
Target/Type
Region
Pre-Clinical
IND
Phase I
Phase II
Pivotal/Phase III
NDA
1First-In-Class (Global Pioneer) Cevira® (APL-1702)
Photodynamic drug-device combination product
Global
Multi-national
Cervical high-grade squamous intraepithelial lesions (HSIL).
Partner:
ASN-1764
Targeted protein degrader
Global
Triple-negative breast cancer
AT-012
USP1
Global
Ovarian cancer and breast cancer
AT-014
Undisclosed
Global
Genitourinary tumors
Other Diseases
Product
Target/Type
Region
Pre-Clinical
IND
Phase I
Phase II
Pivotal/Phase III
NDA
APL-1401
DBH
Global
USA
Moderately to severely active ulcerative colitis
ASN-1733
Undisclosed
Global
Acinetobacter baumannii infection
1 First-In-Class (Global Pioneer)
